GHK-Cu – 100mg

GHK-Cu 100mg research peptide is a lyophilized, copper-binding tripeptide vial supplied by First Class Science at double the peptide mass of the standard 50mg listing, for laboratories running higher-volume or multi-replicate protocols. This page is a research-reference summary for laboratory professionals sourcing this GHK-Cu 100mg research peptide for in vitro and non-clinical investigation — it is not a guide to human or animal use.

In this reference:

• What Is GHK-Cu?
• Proposed Mechanism of Action
• Chemical Identity
• Purity, Storage & Quality
• Research Applications
• What the Human Evidence Shows
• Compared to Related Research Compounds
• Frequently Asked Questions

What Is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide — glycyl-L-histidyl-L-lysine (Gly-His-Lys), complexed with a Cu2+ ion — first isolated from human plasma by researcher Loren Pickart in the 1970s. Circulating GHK-Cu concentration has been reported in the published literature to decline with age, an observation that helped drive several decades of laboratory interest in the peptide’s copper-transport and gene-modulation properties.

This GHK-Cu 100mg research peptide vial supplies twice the total peptide mass of First Class Science’s standard 50mg listing in a single lyophilized (freeze-dried) vial, reconstituted by the receiving laboratory according to its own protocol. Labs running multiple in vitro assays, several animal cohorts, or extended dose-response designs from one lot often choose the 100mg format specifically to avoid combining material from two separate 50mg vials mid-protocol.

It is important for researchers to understand what the published literature does, and does not, establish regardless of vial size. As detailed further down this page, the majority of GHK-Cu’s mechanistic and efficacy data comes from in vitro and animal-model work; controlled human clinical trials of the isolated research compound are limited, and this product is not evaluated or approved by the FDA for any use in humans or animals.

Proposed Mechanism of Action

Study authors have proposed that GHK-Cu’s reported activity in cell and animal models relates to its role as a small, mobile copper carrier that influences gene transcription broadly across the tested genome. A 2015 peer-reviewed review in BioMed Research International reported that GHK-Cu modulated activity of both matrix metalloproteinases and their tissue inhibitors (TIMP-1 and TIMP-2), which study authors proposed functions as a regulatory checkpoint in tissue-remodeling and wound-repair signaling observed in the animal models tested (Pickart, Vasquez-Soltero & Margolina, 2015 — PMC4508379).

A separate 2018 review in International Journal of Molecular Sciences compiled gene-expression research reporting that GHK-Cu, at nanomolar concentrations, was associated with changed expression of a substantial portion of the tested human genome in cell-culture models, with effects concentrated among genes tied to tissue remodeling, antioxidant response, and anti-inflammatory signaling (Pickart & Margolina, 2018 — PMC6073405).

No single receptor has been isolated and confirmed as GHK-Cu’s sole molecular target; study authors themselves describe the peptide’s broad gene-modulation profile as one candidate explanation among several proposed pathways, not an established pharmacological mechanism. Researchers should treat every mechanistic claim in this section as a proposed explanation drawn from a specific published study, not a confirmed fact — a caution that applies equally regardless of which vial size a laboratory orders.

Chemical Identity

CAS Number	49557-75-7
Molecular Formula	C14H24CuN6O4
Molecular Weight	~403.9 g/mol
Sequence	Gly-His-Lys, complexed with Cu2+
Vial Quantity	100mg lyophilized peptide per vial

Note: reported molecular formula and molecular weight for GHK-Cu vary slightly across published sources depending on salt/complex form referenced. Researchers should independently confirm identity data against the batch-specific Certificate of Analysis and PubChem entry before citing in a protocol.

Purity, Storage & Quality

First Class Science supplies this GHK-Cu 100mg research peptide vial at 99% purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result, molecular-weight confirmation, and test date.

Store the lyophilized compound at −20°C for long-term stability; unopened and properly stored, lyophilized peptide is generally stable for extended periods. Because this is a larger single-vial quantity, laboratories reconstituting only a portion of the vial for a given protocol should divide the material into single-use aliquots before reconstitution where practical, and keep unreconstituted lyophilized material frozen until needed — minimizing unnecessary freeze-thaw exposure. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Quality Control Methodology

Each production batch of this GHK-Cu 100mg research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) confirms purity by measuring the proportion of target peptide relative to synthesis by-products or degradation fragments. Mass spectrometry separately confirms molecular identity, verifying that the measured mass matches the expected molecular weight of GHK-Cu. Both results are recorded on the batch’s published Certificate of Analysis, allowing researchers to independently verify the identity and purity of the material used in their protocols.

Who Sources This Research Peptide

Buyers of this GHK-Cu 100mg research peptide are university and academic research laboratories, contract research organizations (CROs), and biotechnology R&D teams running in vitro and animal-model studies on copper-peptide signaling and tissue-remodeling pathways. The larger 100mg format is commonly chosen by labs running replicate studies, multiple cohorts, or higher-volume protocols that would otherwise require multiple separate 50mg orders. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.

Institutional buyers frequently request the Certificate of Analysis for a specific lot in advance of purchase for their own internal quality-assurance records, and First Class Science makes this available on request in addition to the standing copy published for each batch.

Research Applications

The published literature on GHK-Cu spans several distinct preclinical research areas. Each is summarized below strictly as a description of what has been studied in cell-culture and animal models — not as a claim about effects in humans.

Gene Expression & Tissue-Remodeling Research

Cell-culture research has examined GHK-Cu’s association with broad changes in gene-expression patterns, with study authors reporting that nanomolar concentrations of the peptide were linked to altered activity across genes tied to tissue remodeling, antioxidant response, and anti-inflammatory signaling in the models tested (Pickart & Margolina, 2018). Labs running dose-titration series across a range of concentrations from a single lot are one reason researchers select the larger 100mg vial format.

Fibroblast & Collagen Synthesis Research

In vitro fibroblast culture studies have reported that GHK-Cu at low nanomolar concentrations was associated with stimulated collagen and elastin synthesis and upregulated extracellular-matrix genes, without a corresponding increase in non-collagen protein production in the models tested. Researchers use this line of study to examine copper-dependent regulation of matrix-remodeling enzymes across multiple cell lines or passages.

Dermal Wound-Model Research

Preclinical wound-model research has reported measures of accelerated closure rate and graft-survival improvement in tested animal models following topical or local application of GHK-Cu-containing preparations, alongside reported anti-inflammatory activity attributed to the peptide in those specific studies. This research is confined strictly to animal wound models and in vitro assays and does not establish an effect in human skin.

Angiogenesis & Metalloproteinase-Regulation Research

Separate preclinical work has examined GHK-Cu’s association with modulation of matrix metalloproteinases and their inhibitors, and with markers of new blood-vessel formation (angiogenesis) in tested animal and cell-culture models — a pathway study authors connect to the broader tissue-remodeling signaling described in the mechanism section above.

Copper Homeostasis & Enzyme-Cofactor Research

Separately from its gene-modulation profile, GHK-Cu’s research interest is connected to copper’s broader role as an essential enzymatic cofactor. Copper-dependent enzymes such as lysyl oxidase, which crosslinks collagen and elastin fibers, and superoxide dismutase (SOD), an antioxidant enzyme, are both studied in the tissue-remodeling and oxidative-stress literature. Researchers examining GHK-Cu often situate its reported activity within this larger body of copper-biochemistry research, using it as a tool compound to study copper-transport and copper-dependent enzyme regulation in cultured cells rather than as a standalone finding. Labs working from a single 100mg lot across several such assay types are one reason this larger vial size is requested.

What the Human Evidence Shows

Researchers evaluating GHK-Cu should be aware of an important gap between the cell-culture and animal literature summarized above and the controlled human evidence base for the isolated research compound. Separately from this research peptide, formulated cosmetic products containing copper peptides have been studied in the dermatology and cosmetic-science literature for skin-appearance parameters — but those studies examine finished, formulated cosmetic products, not the unformulated research peptide sold on this page, and they do not establish a clinical or medical use for this product.

No controlled human clinical trials of the isolated GHK-Cu research compound establishing a disease-related use were identified in the literature reviewed for this page. This is consistent with GHK-Cu’s regulatory status: it is not an FDA-approved drug, has not completed controlled human clinical trials for any medical indication, and is not evaluated by the FDA for safety or efficacy in humans or animals for any condition.

We include this section because researchers deserve an accurate picture of the evidence base, not just the parts that sound most compelling. The cell-culture and animal-model literature on GHK-Cu’s gene-modulation and tissue-remodeling activity is real and well-documented; the absence of controlled human clinical-trial data establishing a medical use for the isolated compound is equally real and belongs in the same conversation. A researcher citing this literature in a grant application, protocol design, or comparative study should characterize these findings accurately as preclinical, in vitro or animal-model results — a distinction that holds regardless of vial size ordered.

Compared to Related Research Compounds

GHK-Cu is supplied by First Class Science across several dose points and formats for researchers running comparative or format-specific studies:

GHK-Cu – 50mg supplies the same lyophilized copper-binding tripeptide at half the total peptide mass of this listing, for laboratories running smaller-scale protocols or a single cohort that does not require the full 100mg quantity.

GHK-Cu (Lyophilized) – 50mg is First Class Science’s separately listed 50mg SKU, also supplied as lyophilized powder, distinguished in the catalog primarily by packaging/pricing tier rather than a different chemical entity.

GHK-Cu Capsules – 2mg supply the same research peptide in an oral-research capsule format rather than lyophilized powder for reconstitution, for laboratories whose protocols call for oral-route administration models.

Klow Blend – 50/10/10/10mg combines this same GHK-Cu compound with BPC-157 and TB-500 in a single multi-peptide vial, for researchers modeling combined-pathway tissue-repair protocols rather than a single-compound design.

Each of these related preparations carries its own Certificate of Analysis and is subject to the same research-use-only terms described on this page. Laboratories choosing the 100mg format over the 50mg listings typically do so to reduce the number of separate orders and lot changes required across a multi-cohort or dose-titration study design.

Common Research Study Designs

Published studies referenced throughout this page typically fall into one of several designs: in vitro cell-culture assays examining gene-expression or matrix-enzyme changes following peptide exposure at a range of concentrations, and controlled rodent or rabbit wound-model studies comparing treated and untreated groups on a defined healing-rate or biomechanical outcome measure. Understanding which design underlies a given finding is important context for interpreting the strength of any individual claim in the literature, since a cell-culture finding and a controlled animal-model finding carry different evidentiary weight — and both carry different weight again from the still-limited controlled human data discussed above.

Concentration-response designs, in which cultured cells or tissue samples are exposed to a range of GHK-Cu concentrations to identify a dose-dependent effect on a given marker, are also common across the gene-expression and fibroblast literature summarized on this page — a design that benefits from the larger single-lot 100mg quantity this listing supplies. Researchers replicating a published design should independently confirm the original study’s exact peptide concentration, exposure duration, and model system before drawing any comparison to their own results.

Frequently Asked Questions

What is the purity of this GHK-Cu 100mg research peptide?
Every batch is independently verified at 99% purity via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.

How should GHK-Cu research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

How does this 100mg vial differ from the 50mg listing?
The two listings supply the identical GHK-Cu compound at the same 99% purity standard; the difference is total peptide mass per vial (100mg versus 50mg), which changes how many reconstitutions, replicate protocols, or dose-titration steps a single vial can support without ordering additional vials mid-study.

Is one 100mg vial equivalent to two 50mg vials?
Both supply the same total peptide mass from a purity standpoint, but a single 100mg vial comes from one lot and one Certificate of Analysis, which some protocols prefer over combining material from two separately lotted 50mg vials.

Is GHK-Cu approved for human or animal use?
No. GHK-Cu as sold here is not an FDA-approved drug and has not completed controlled human clinical trials for any medical indication. It is sold exclusively for in vitro and animal-model laboratory research.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.

Can GHK-Cu research peptide be combined with other compounds in a study design?
Some published research examines GHK-Cu alongside other tissue-repair-associated peptides in combined-pathway models; First Class Science also supplies a pre-blended multi-peptide vial (see Klow Blend above) for laboratories whose protocol calls for a fixed combination ratio rather than separately sourced single-compound vials.

Shipping, Handling & Compliance

This GHK-Cu 100mg research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records. Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or clinical research contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.